FIG. 2.

In vivo antitumor activity of MV-GMCSF-antiCEA in an immunocompetent murine colon carcinoma model. MC38cea cells (10⁶) were implanted subcutaneously into the right flank of 6- to 8-week-old C57BL/6 mice. When tumor volumes reached 30–50 μl, mice were treated intratumorally with carrier fluid (mock; n=10), 10⁶ particles of UV-inactivated MV-GMCSF-antiCEA (UV-MV; n=10), 10⁶ particles of MV-EGFP-antiCEA (n=10), or 10⁶ particles of MV-GMCSF-antiCEA (n=9), each on four consecutive days (days 5, 6, 7, and 8 postimplantation). Tumor volumes were measured every third day. (A) Blood was collected at the indicated time points after tumor implantation and an ELISA was performed to evaluate GM-CSF serum levels. (B) Tumor volume was measured every third day. (C) Distribution of tumor volumes on day 16 postimplantation. Each dot represents one mouse. (D) Kaplan–Meier plot documenting survival effects of MV-GMCSF-antiCEA and MV-EGFP-antiCEA compared with mock- or UV-MV-treated mice. Mice were sacrificed when tumors reached a volume of 1500 μl or when severe ulceration occurred. Circles, mock treatment; asterisks, UV-MV; triangles, MV-EGFP-antiCEA; squares, MV-GMCSF-antiCEA.